The present disclosure provides a lateral flow device, and methods of use of the device, for accurately and rapidly detecting a COVID-19 infection in a subject. The lateral flow device described herein detects in a liquid sample from the subject the presence or absence of neutralizing and non-neutralizing anti-S1 spike antibodies as IgM and IgG types. The anti-S1 antibodies neutralizing antibodies (e.g., both IgM and IgG) can block binding between ACE2 antigen and S1 spike protein which is the basis for the design of the lateral flow device.

A method is provided that includes intranasally dispensing nasal wash fluid (26) into a nasal cavity (22) of a subject such that the nasal wash fluid (26) washes biological material into an oropharynx (30) of the subject from (a) the nasal cavity (22), (b) a nasopharynx (32) of the subject, or (c) the nasal cavity (22) and the nasopharynx (32). Thereafter, a specimen sample (24) is collected that passed out of an anterior opening (34) of an oral cavity (36) of the subject and contains at least a portion of the biological material washed into the oropharynx (30) by the nasal wash fluid (26). Other embodiments are also described.

The present disclosure provides methods and kits for detecting adeno-associated viruses. In some embodiments, the adeno-associated virus is Anc80. Detection methods include HPLC- and ELISA-based methods.

The present application is related to a detection device and method for coronavirus and influenza virus. The device comprises a detection module (20), a signal processing circuit (30), a controller (40), a displayer (50), a digital-to-analog conversion circuit (60), and a clock (70). Noticeably, the detection module (20) comprises a sample cell, and a transistor sensor combination integrated in the sample cell and used for measuring different targets. The detection module (20) may comprise a sample cell array to realize simultaneous detection of a plurality of samples to be detected. The detection method comprises the following steps: adding a sample to be detected into a sample cell, reading an electrical signal response of each transistor sensor in the sample cell to judge whether the sample to be detected contains a virus to be detected or not. The present application belongs to the technical field of biological detection.

The disclosure relates to systems and devices for diagnosing infectious disease (e.g., bacterial or viral infections). More particularly, the disclosure relates to acoustic sensors for detecting infectious disease caused by viral infections (e.g., coronavirus, rhinovirus, influenza, etc.).

Disclosed herein are recombinant antibodies or the fragment thereof for detecting severe acute respiratory syndrome coronavirus (SARS-CoV). According to some embodiments, the SARS-CoV is SARS-CoV-1. According to some alternative embodiments, the SARS-CoV is SARS-CoV-2. Also disclosed herein are a kit comprising the recombinant antibodies, and a method for diagnosing the infection of SARS-CoV by using the recombinant antibody or the kit.

The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

Embodiments of the present invention are directed to a test kit. The test kit includes an assay tube and a reagent cap. The assay tube includes a sample opening in the assay tube for receiving a sample and a lateral flow assay (“LFA”) test strip in the assay tube in communication with a sample opening. The reagent cap is designed to be placed over the assay tube and includes a buffer. When the reagent cap is placed over the sample opening of the assay tube the buffer is released over the sample to carry an analyte over the LFA test strip.

A novel method of detecting and destroying viral transmissions such as SARS-CoV-2 transmission is described. The proposed technique uses a light source such as that from a smart phone and a mobile spectrophotometer to enable detection of proteins in solution. The technique allows for detecting soluble preparations of for example spike protein subunits from SARS-CoV-2, followed by detection of the actual binding potential of the spike protein with its host receptor, for example the angiotensin-converting enzyme 2 (ACE2) or other antigens or elements. The results are validated by showing that this method can detect antigen-antibody binding using two independent protein-antibody pairs. Finally, this technique is combined with DC bias to show that introduction of a current in the system can be used to disrupt the antigen-antibody reaction, suggesting that this technique can be a powerful means of disrupting virus transmission by destroying virus-receptor interactions.